<DOC>
	<DOC>NCT01067807</DOC>
	<brief_summary>Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations</brief_summary>
	<brief_title>Proellex Pharmacokinetics Bridging Study</brief_title>
	<detailed_description>Healthy female subjects received a single dose of four different types of Proellex, the original 25 mg dose and three new formulations (24 and 50 mg dose). Blood was collected pre-dose, at specified intervals and 24 hours post dose. Each dose was separated by at least one week interval from the previous dose.</detailed_description>
	<criteria>Medically normal subjects with no significant abnormal findings at the screening physical examination as evaluated by the clinical Investigator Subject was willing to remain in the clinic for the screening visit; and for the treatment visits (day 1, day of treatment and day 1; approximately 36 hrs per treatment visit) Postmenopausal women, Subject with documented endometriosis Subject with known uterine fibroids or vaginal polyps</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>